% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dexter_egghead dexter_egghead Dec 15, 2005 2:48 PM Flag


    Well it seems obvious BSX products are inferiior and continue to kill people, since doctors are afraid to use them due to litigation, and malpractice suits, BSX will continue to lose money and languish.
    Studies Give Edge To J&J Stent
    Matthew Herper, 08.16.05, 4:00 PM ET

    NEW YORK - Johnson & Johnson has a better product than its rival, Boston Scientific, for holding open clogged arteries.

    New data published in the two leading medical journals indicates that patients who receive Cypher, a drug-coated stent made by Johnson & Johnson (nyse: JNJ - news - people ), are less likely to need a repeat surgery than those who get Taxus, a rival stent from Boston Scientific (nyse: BSX - news - people ).

    That's more bad news for Boston Scientific, which has seen shares drop 30% since September 2004 amid concerns over its over-reliance on drug-coated stents.

    "There is a difference," says David J. Moliterno, a cardiologist at the University of Kentucky who wrote an editorial on the studies in The New England Journal of Medicine.
    For all patients taken as a group, Moliterno says, those who receive Taxus are far more likely to need their procedure redone than those who receive Cypher.

    High-risk patients, such as those with diabetes, also fare better with the Cypher stent, he says.

    Samin Sharma, a cardiologist at the Mount Sinai School of Medicine, say she thinks most doctors would opt to use Cypher if it weren't for persistent manufacturing problems that can make the device harder for doctors to get. He notes that the evidence is consistent that Cypher is better at preventing arteries from reclogging.

    The researchers found that patients receiving Cypher were at much lower risk of having their arteries reclose than those who received Taxus. The results are published in the current issue of The Journal of the American Medical Association. Says Firth, "I think the value of this product from a health economics standpoint is very clearly demonstrated."

    Meanwhile, J&J says the U.S. Food and Drug Administration has visited new manufacturing plants that would finally allow it to churn out more Cypher stents.

22.56+0.17(+0.76%)May 26 4:01 PMEDT